Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersPeter Horak, Klaus Schulze‐Osthoff, Arne Jahn et al.|Cancer Discovery|2021Cited by 282
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)Claire Harrison, Vincent Ribrag, Jean‐Jacques Kiladjian et al.|Blood|2015Cited by 39
Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML CellsDaniel B. Lipka, Thomas Fischer|PLoS ONE|2012Cited by 21
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk MyelofibrosisJean‐Jacques Kiladjian, Claire Harrison, Florian H. Heidel et al.|Blood|2014Cited by 14